Edition:
India

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

83.60CHF
23 Jan 2018
Change (% chg)

-- (--)
Prev Close
CHF83.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,430,526
52-wk High
CHF85.40
52-wk Low
CHF69.50

Select another date:

Mon, Jan 22 2018

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.

UPDATE 1-Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH, Jan 17 Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.

Novartis gets U.S. priority review for Kymriah for adults with lymphoma

ZURICH, Jan 17 Novartis has been ‍granted priority review for its cell therapy Kymriah for adults with a form of lymphoma by the U.S. Food and Drug Administration, the Swiss drugmaker said on Wednesday, as it seeks to expand use of the treatment in multiple blood cancers.

BRIEF-FDA accepts Novartis submission of biosimilar version of Humira

* SANDOZ REGULATORY SUBMISSION FOR PROPOSED BIOSIMILAR ADALIMUMAB ACCEPTED BY FDA

Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH, Jan 4 Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

MEDIA-Novartis's diclofinac injection flagged by India health ministry panel - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

Novartis breast cancer therapy gets FDA breakthrough designation

ZURICH Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

Novartis breast cancer therapy gets FDA breakthrough designation

ZURICH, Jan 3 Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

Select another date: